--- title: "Urine-Based Molecular Testing Service" ocid: "ocds-h6vhtk-06df03" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06df03" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-06df03.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-06df03.json" source: "Find A Tender Service" current_stage: "Planning" buyer: "UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST" published: "2026-08-07" --- # Urine-Based Molecular Testing Service Buyer: UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST Current stage: Planning OCID: ocds-h6vhtk-06df03 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06df03) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-06df03.json) ## Summary The University Hospitals of North Midlands NHS Trust is initiating a procurement process for a urine-based molecular testing service, as per the Health Care Services (Provider Selection Regime) Regulations 2023. This procurement is not governed by the Public Contracts Regulations 2015 nor the Procurement Act 2023. The tender, titled "Urine-Based Molecular Testing Service," is in the planning stage, with services to be delivered from 1 October 2026 to 31 March 2027 in the Stoke on Trent area (region UKG23). The contract is valued at £90,000 and falls under the health services category, identified by CPV code 85100000. The procurement will follow the Most Suitable Provider process to ensure the selection of a service that aligns with the Trust's specified requirements. This tender represents a significant opportunity for businesses specialising in molecular diagnostic testing, particularly those qualified to provide urine-based tests for non-visible haematuria. The contract's focus on reducing unnecessary cystoscopy and improving patient experience could attract businesses with innovative and patient-centred solutions. Suppliers with capabilities in providing robust logistical solutions for home sample collection, efficient laboratory analysis, and rapid reporting of results will be especially well-suited. Companies that can ensure compliance with strict service levels, quality controls, and clinical governance requirements are encouraged to compete, potentially leading to expanded operations and enhanced partnership with a major NHS Trust. ## Notice Contract for a Urine-Based Molecular Testing Service ### Lot Information Lot 1 UHNM requires a urine-based molecular testing service from 1 October 2026 to 31 March 2027 to support triage of eligible patients on the non-visible haematuria pathway. The service must provide a safe, non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort, while maintaining clinical oversight, safety-netting and rapid escalation for patients with positive or high-risk results. Scope: The service will apply to patients referred to the UHNM non-visible haematuria pathway who meet locally agreed eligibility criteria. The provider must support home urine sample collection where required, sample return logistics, laboratory analysis, secure reporting of results, and operational data provision. Visible haematuria pathways, confirmed bladder cancer management, and patients requiring cystoscopy for other clinical indications are excluded from scope unless otherwise agreed. Core provider responsibilities: The supplier must provide clear patient instructions, sample kits and return arrangements where applicable; maintain robust sample identification and chain-of-custody; undertake analysis against the defined bladder cancer-associated molecular panel; apply documented quality controls; manage rejected or insufficient samples promptly; and return results in a format that enables UHNM clinicians to categorise patients as negative/low-risk or positive/high-risk for onward pathway action. Minimum service levels: Results should be available to UHNM within 7 calendar days of sample receipt, with at least 90% compliance. Kits should be issued within 2 working days of eligibility confirmation where applicable. Non-conforming samples must be notified to UHNM within 1 working day, with clear re-collection instructions. Results must be returned through an agreed secure channel and be suitable for recording in the patient record. Clinical governance and safety: The service must operate within agreed UHNM clinical decision rules, including eligibility criteria, exclusions, result interpretation, escalation routes and safety-netting for negative results. Reporting requirements: The provider and UHNM pathway team must support collection of referral date, eligibility decision date, kit dispatch date, sample receipt date, result date/time, result category, clinical action date and final pathway outcome. A monthly KPI dashboard and quarterly clinical governance pack must be available to monitor turnaround times, sample rejection, result-to-action time, activity delivered, cystoscopy avoidance, patient experience, equity of access and pathway safety. Implementation expectations: Mobilisation should be completed within 4 weeks, including confirmation of eligibility criteria, clinical decision rules, reporting routes, patient materials, logistics and baseline data. A 3-month pilot evaluation should assess operational performance, safety signals, patient experience and cystoscopy avoidance, followed by business-as-usual delivery from month 4 where agreed. A full review should determine clinical effectiveness, capacity release, safety, and value for money. Procurement outcome sought: UHNM is seeking a provider capable of delivering a reliable, governed, auditable and patient-centred molecular urine testing service that reduces unnecessary cystoscopy for eligible non-visible haematuria patients, releases urology capacity, improves patient experience, and maintains timely escalation for patients requiring further diagnostic assessment. The contract duration is from 1 October 2026 to 31 March 2027. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/075257-2026 | | Notice type | Planning Notice | | Procurement type | Standard | | Procurement category | Services | | Procurement method | Not Specified | | Procurement method details | Not specified | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Planning | ## Dates | Field | Value | | --- | --- | | Publication date | 7 Aug 2026 | | Submission deadline | Not specified | | Future notice date | 6 Aug 2026 | | Award date | Not specified | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £90,000 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Planned | | Lots status | Planned | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST | | Locality | STOKE ON TRENT | | Post town | Stoke-on-Trent | | Postcode | ST4 6QG | | Country | England | | ITL 1 | TLG West Midlands (England) | | ITL 2 | TLG2 Shropshire and Staffordshire | | ITL 3 | TLG23 Stoke-on-Trent | | Local authority | Stoke-on-Trent | | Electoral ward | Penkhull & Springfields | | Westminster constituency | Stoke-on-Trent Central | | Delivery location | TLG23 Stoke-on-Trent | ## CPV Codes ### Divisions - 85 - Health and social work services ### Codes - 85100000 - Health services ## Release History - 7 Aug 2026 at 11:17 - Planning - Planning Notice - https://www.find-tender.service.gov.uk/Notice/075257-2026 ## Notice URLs - https://atamis-1928.my.site.com/s/Welcome - https://www.uhnm.nhs.uk/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06df03. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-06df03.json.